TESK1
MOLECULAR TARGETtestis associated actin remodelling kinase 1
TESK1 (testis associated actin remodelling kinase 1) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting TESK1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | foretinib | 4.34 | 76 |
| 2 | tozasertib | 4.33 | 75 |
| 3 | vandetanib | 4.30 | 73 |
| 4 | canertinib | 3.53 | 33 |
| 5 | fedratinib | 3.40 | 29 |
| 6 | jnj 7706621 | 3.09 | 21 |
| 7 | lestaurtinib | 3.04 | 20 |
| 8 | r 406 | 2.83 | 16 |
| 9 | plx 4720 | 2.71 | 14 |
| 10 | ast 487 | 2.56 | 12 |
| 11 | golvatinib | 2.20 | 8 |
| 12 | osi 632 | 1.79 | 5 |
| 13 | Axitinib | 0.69 | 1 |
| 14 | Crizotinib | 0.69 | 1 |
| 15 | Dasatinib | 0.69 | 1 |
About TESK1 as a Drug Target
TESK1 (testis associated actin remodelling kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented TESK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
TESK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.